Skip to main content
Fig. 6 | Journal of Biomedical Science

Fig. 6

From: Small heterodimer partner (SHP) aggravates ER stress in Parkinson’s disease-linked LRRK2 mutant astrocyte by regulating XBP1 SUMOylation

Fig. 6

Doxycycline improves LRRK2-GS astrocyte viability by suppressing SHP expression. A LRRK2-WT or myc-SHP transfected LRRK2-GS astrocytes were treated with tunicamycin in the absence or presence of doxycycline (Dox) for 24 h. Expression levels of the indicated mRNAs were analyzed by real-time qPCR. B Immunoprecipitation pulling down XBP1 in tunicamycin-treated LRRK2-WT and -GS astrocytes in the absence or presence of doxycycline. C Organotypic slices from LRRK2-WT and -GS mice were treated with tunicamycin for 48 h in the absence or presence of doxycycline (50 μM). Representative images (upper) and summary data (lower) show MAP2 and TUNEL staining. Four fields of view per group of three independent experiments (n = 12). Scale bar, 100 μm. Data are means ± SD (*p < 0.05, **p < 0.01). D Overview of experimental timeline. Doxycycline (5 μg/g) treatment was initiated 1 d pre-injection (DMSO or tunicamycin) and then continued for the duration of the experiment. The fluorescence intensities of MAP2 per field and CHOPpos cell numbers were quantified and displayed graphically. Scale bar: 50 μm. Data are means ± SD (*p < 0.05). n = 4–5/group

Back to article page